<DOC>
	<DOCNO>NCT01191385</DOCNO>
	<brief_summary>This study international prospective , open-label , multi-center , non-interventional study . The protocol allow enrollment patient diagnosis HCC decision treat sorafenib make time study enrollment . All patient followed-up withdrawal consent , lose follow-up , death , end study . Detailed information concern past medical/surgical history , performance status , method diagnosis staging , etc . patient HCC collect , practice pattern physicians involve care patient HCC real-life condition evaluate .</brief_summary>
	<brief_title>GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar Individual Study Start</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Outpatients histologically/cytologically document radiographically diagnose HCC decision treat sorafenib make time . Radiographic diagnosis need typical finding HCC radiographic method i.e . multidimensional dynamic CT , CT hepatic arteriography ( CTHA ) /CT arterial portography ( CTAP ) MRI . Patients must sign informed consent form Patients must life expectancy least 8 week Patients decision treat sorafenib make time study start Patients receive sorafenib past currently treat sorafenib Hospice patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HCC</keyword>
	<keyword>Liver cancer</keyword>
	<keyword>Cancer liver</keyword>
	<keyword>Cancer , liver</keyword>
	<keyword>Hepatic cancer</keyword>
	<keyword>Cancer , hepatic</keyword>
	<keyword>Carcinoma , hepatocellular</keyword>
</DOC>